Unbiased headlines. Facts, not spin.
Unbiased Headlines is an independently owned news organization. We bring you the facts, not opinions, written fresh from 110+ named sources. Sources linked so you can verify it yourself.
White House Withdraws Heidi Overton's FDA Nomination Before Senate Committee Vote; Cassidy Cites Abortion-Pill Dispute

Since Trump picked Overton in August to replace Marty Makary, who resigned in May, her nomination had been heading toward a Senate HELP Committee vote scheduled for Wednesday, Nov. 18. On Tuesday, Nov. 17, the White House withdrew it before that vote could take place.
A White House official confirmed the withdrawal to several outlets and gave no reason. Axios was first to report it.
Two explanations for why it collapsed
Three people familiar with the matter told Reuters the nomination was pulled because it lacked enough support in Congress. Republicans hold a one-vote edge on the committee, so a single GOP defection could have sunk it.
Sen. Bill Cassidy, R-La., the committee chairman, offered a different account in a statement on X. He said Overton had a "viable confirmation path" and that his conversations with members led him to believe she could be confirmed.
Cassidy said the key issue that blocked her path was the White House's resistance to meeting the demands of anti-abortion senators, who have been pushing the administration to further restrict access to abortion pills. The White House did not immediately respond to a request for comment on his claim.
The two accounts are not necessarily in conflict. But they point the blame in different directions, and only Cassidy has said so on the record.
The mifepristone problem
Overton is an openly anti-abortion physician. At her September hearing she called the FDA's mifepristone safety review a priority but declined to say whether the drug is safe and effective when senators from both sides asked.
The FDA has said that review will conclude by March 2027.
Sources told CBS News that Sen. Josh Hawley, R-Mo., was among the skeptics because Overton sidestepped questions on how she would handle the mifepristone safety study. The Susan B. Anthony group urged the Senate to delay her confirmation and wants the FDA to commit to banning mail orders of mifepristone.
Two Republicans who back abortion access, Susan Collins of Maine and Lisa Murkowski of Alaska, had not said how they would vote. None of the Democrats on the committee were expected to back her, per CBS's sources.
Vaccines, vaping and MAHA
Overton had other problems. She stood beside Trump on Aug. 10 when he signed an executive order calling for fewer federally recommended childhood vaccines and for breaking up the MMR shot into three separate injections.
At her hearing, she told Cassidy that "the MMR vaccine is safe and effective." Sen. Ed Markey, D-Mass., asked why she had not corrected Trump in the Oval Office.
Cassidy had previously cited her "lack of managerial experience" and said her role in the vaccine order "calls into question her commitment to standing up for sound science and protecting children's health." Reuters' sources said her support of the order also unnerved several medical groups and career FDA officials.
Supporters of HHS Secretary Robert F. Kennedy Jr.'s "Make America Healthy Again" movement opposed her too, arguing she would not sufficiently challenge corporate interests. She also drew fire over her execution of the administration's pro-vaping policies on the Domestic Policy Council.
What comes next
The White House has not named a new nominee. Two sources told Semafor and CBS that the administration is weighing Sen. Roger Marshall, R-Kan., a physician and HELP Committee member. Marshall lost his reelection bid to Democrat Adam Hamilton earlier this month.
CBS's sources also said the White House has talked to candidates who could serve in an acting capacity, which would skip Senate confirmation altogether.
Timing is tight. Republicans lost control of both chambers in this month's midterms, and Cassidy and Marshall are among the HELP Committee members who lost their own races. The administration was seeking a confirmed commissioner before control of Congress flips in the new year, which would likely make any pick more difficult. CBS describes the remaining legislative window as about three weeks.
Meanwhile, the agency has gone months without a confirmed leader; Kyle Diamantas has served as acting commissioner since Makary's departure. Reuters reports the FDA has lost more than 4,500 staff over the past year, and it employs more than 18,000 people. It oversees products that account for roughly 20% of consumer spending.
The White House now has two decisions to make: whether to move a replacement through the committee in the weeks left or install an acting commissioner, and whether to give anti-abortion senators the mifepristone commitments Cassidy says stalled this nomination.
Sources used for this briefing
5 links from 5 independent newsrooms (syndicated copies of the same report count once)
These are the sources it draws on, linked so you can verify.